Clinical Trial Update: Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor-positive, HER2-negative brea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Letrozole (letrozole)
• Palbociclib (palbociclib)

Snippet

Sponsor: Georgetown University | Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-08-20